文献速递脊柱关节炎

生物制剂治疗银屑病关节炎的疗效与安全性:系统综述与网络荟萃分析

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
PubMed 文献 · RMD Open · 2020-01-01

该研究采用贝叶斯网络荟萃分析,在bDMARD初治的PsA患者中比较获批bDMARDs第12-16周的ACR、PsARC和PASI应答,并在混合人群中评估安全性。结果显示除阿巴西普外所有治疗在ACR上均优于安慰剂,英夫利西单抗最有效,各治疗间安全性差异较少。

要点

  • 除阿巴西普外,所有bDMARDs在ACR应答上均统计显著优于安慰剂。
  • 英夫利西单抗ACR疗效最佳,戈利木单抗和依那西普次之且优于多数其他治疗。
  • 安全性终点分析显示各治疗间差异较少。

核心结论

  • 该网络荟萃分析证实bDMARDs在活动性PsA患者中具有疗效和可接受的安全性。
  • 大多数治疗之间通常仅有少数统计显著差异。

研究设计与样本

  • 采用贝叶斯网络荟萃分析比较获批bDMARDs的临床疗效。
  • 疗效在bDMARD初治PsA患者第12-16周评估ACR、PsARC和PASI应答。
  • 安全性终点在bDMARD初治和经治的混合总体中评估。

主要发现

  • ACR应答方面,除阿巴西普外所有治疗均统计显著优于安慰剂。
  • 英夫利西单抗最有效,戈利木单抗和依那西普统计显著优于大多数其他治疗。
  • Ixekizumab 80 mg每2周方案统计显著优于阿巴西普皮下、阿普米司特和两种乌司奴单抗方案。
  • Ixekizumab 80 mg每4周方案观察到相似结果。
  • PsARC应答方面,Ixekizumab与其他治疗无显著差异,但戈利木单抗、英夫利西单抗和依那西普优于包括Ixekizumab在内的大多数其他药物。

关键数值与推荐

  • PASI应答方面,英夫利西单抗数值上最有效,但未统计显著优于表现次佳的Ixekizumab。
  • 安全性终点分析发现各治疗间差异较少。

临床怎么用

  • 可参考本网络荟萃分析结果在bDMARD初治PsA患者中选择生物制剂。
  • 英夫利西单抗在ACR和PASI应答上表现突出,但需结合安全性个体化决策。

局限性

  • 大多数治疗之间通常仅有少数统计显著差异,需谨慎解读排序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs are used in patients with psoriatic arthritis (PsA), but few studies directly compare their clinical efficacy. In such situations, network meta-analysis (NMA) can inform evidence-based decision-making. OBJECTIVE: To evaluate the comparative efficacy and safety of approved bDMARDs in patients with PsA. METHODS: Bayesian NMA was conducted to compare the clinical efficacy of bDMARDs at weeks 12‒16 in bDMARD-naïve patients with PsA in terms of American College of Rheumatology (ACR) criteria, Psoriatic Arthritis Response Criteria (PsARC) and Psoriasis Area and Severity Index (PASI). Safety end points were evaluated in the overall mixed population of bDMARD-naive and bDMARD-experienced patients. RESULTS: For ACR, all treatments except abatacept were statistically superior to placebo. Infliximab was most effective, followed by golimumab and etanercept, which were statistically superior to most other treatments. Ixekizumab 80 mg every 2 weeks (Q2W) was statistically superior to abatacept subcutaneous, apremilast and both regimens of ustekinumab; similar findings were observed for ixekizumab 80 mg Q4W. For PsARC response, ixekizumab did not significantly differ from other therapies, except for golimumab, infliximab and etanercept, which were superior to most other agents including ixekizumab. For PASI response, infliximab was numerically most effective, but was not statistically superior to ixekizumab, which was the next best performing agent. Analysis of safety end points identified few differences between treatments. CONCLUSION: Our NMA confirms the efficacy and acceptable safety profile of bDMARDs in patients with active PsA. There were generally few statistically significant differences between most treatments.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ruyssen-Witrand A, Perry R, Watkins C, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020. PMID: 32094304. doi:10.1136/rmdopen-2019-001117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。